Nicholas Short

203PUBLICATIONS
263CO-AUTHORS
Medical molecular engineering of nucleic acids and proteinsHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (203)

|Aug 13, 2026
Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia.

|Jul 22, 2026
Results of second-line therapy in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.

|Jul 16, 2026
Predictors of survival in adults with B-cell acute lymphoblastic leukemia treated with blinatumomab and/or inotuzumab ozogamicin in first salvage.

|Jun 27, 2026
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.

|Jun 22, 2026
Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia.

|May 27, 2026
Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML.

Pageof 34

Frequent Collaborators

127 joint publications

Elias Jabbour

119 joint publications

Hagop M Kantarjian

114 joint publications

Tapan M Kadia

110 joint publications

Navel G Daver